Advances In Alzheimer Research

Alzheimer’s disease (AD) is currently recognized as an untreatable, progressive, degenerative and terminal disease that is globally afflicting an estimated 36 million people and this number is growing in an unabated and frightening manner. Advances in Alzheimer Research, provides researchers with an integrated approach to AD academic literature ranging from basic to advanced clinical research. The series highlights the latest information in order to unravel the origin, pathogenesis and prevention of AD. The purpose of this book series is, therefore, to capture and discuss both, improvements towards the diagnosis and potential treatment of AD by established and novel strategies. This first volume of the series provides an important mechanism to bring individuals having a variety of scientific interests and expertise under one roof to specifically focus on AD and related dementias. This volume presents articles on beta amyloid protein targets as well as research on secretase enzyme systems among other topics that deal with AD therapy.

Recent Advances in Alzheimer Disease Research is a book series focusing on contemporary research on Alzheimer’s disease epidemiology, pathophysiology, diagnosis and therapy. The series features reviews by experts in neuroscience and aims to provide current information in the field to both researchers and clinicians. Down syndrome is a chromosomal disorder affecting more than 5.8 million individuals worldwide. Down syndrome can be viewed as a complex multi-system disorder as it manifests into significant physical, psychological, and cognitive abnormalities in affected persons. With aging, most adults with Down syndrome develop the clinical and neuropathological hallmarks of Alzheimer's disease. Unfortunately, no extant treatments have proven beneficial for cognitive dysfunction for either Down syndrome or Alzheimer’s disease. An incomplete understanding of the common pathogenic mechanisms that link these two disorders has limited researchers’ progress to this end. Common Pathogenic Mechanisms between Down syndrome and Alzheimer's Disease: Steps toward Therapy is a novel attempt to fill this void, by summarizing the work of world-renowned scientists in the field of Alzheimer’s disease and Down syndrome, and thus providing an unprecedented opportunity to attract attention to Down syndrome as a tool for understanding the common molecular mechanisms that underlie Alzheimer’s disease and to develop new therapies for similar neurodegenerative disorders of the brain. The book covers the fundamental pathophysiology and molecular mechanisms behind the incidence of Alzheimer’s disease in Down syndrome affected individuals as well other key topics such as diagnosis and management, in vivo brain imaging studies, and progressive neurodegeneration of the monoaminergic system. The book concludes with a review of recent clinical trials of drugs designed to mitigate cognitive dysfunction in aging adults with Down syndrome and establishes a scientific warrant for the increased testing of candidate pharmacotherapies. Common Pathogenic Mechanisms between Down syndrome and Alzheimer's Disease: Steps toward Therapy is a useful reference clinicians involved in treating Down syndrome patients as well as for neuroscience researchers seeking to understand the influence of a specific case of aneuploidy on Alzheimer’s disease incidence and its progression at the molecular level.

Alzheimer’s disease (AD) is currently recognized as an untreatable, progressive, degenerative and terminal disease that is global – afflicting over 36 million people worldwide, with the number growing in an unabated and frightening manner. The goal of the series Advances in Alzheimer’s Research , with Volumes 1 and 2, is to provide an integrated approach to AD from basic and clinical research and to highlight the valuable information in order to unravel the origin, pathogenesis and prevention of AD. The aim of this book is to both capture and discuss improvements toward the diagnosis and potential treatment of AD by both established and novel strategies. This book series, including the Volume 2, provides an important mechanism to bring under the same roof a variety of scientific interests and expertise to specifically focus on AD and related dementias. The fullest attempt has been made to disseminate the most current knowledge on recent advances in potential therapy of AD.

Alzheimer's disease is the most frequent cause of dementia that slowly and progressively causes cognitive impairment and profoundly alters the daily activities of the patients. Approximately, ten percent of all persons over the age of seventy experience significant memory loss, and in more than half of the cases, the cause is Alzheimer's disease. This reference book is an update on the most relevant pathological and clinical findings of this neurological disorder. Chapters cover the basic hypothesis of Alzheimer’s disease, pathological features of the disease in the brain, Alzheimer’s disease diagnosis and therapy. Information provided in the book is focused on research in developed countries. The book offers students of medicine and nursing as well as medical practitioners and specialists (internists, neurologists, gerontologists, and psychiatrists), the necessary information to understand the pathological and clinical aspects of the disease in depth, with the goal of improving medical outcomes in the care of their patients.

Alzheimer's disease (AD), is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. The cause and progression of Alzheimer's disease are not well understood. Research indicates that the disease is associated with plaques and tangles in the brain. Current treatments only help with the symptoms of the disease. There are no available treatments that stop or reverse the progression of the disease. As of 2012, more than 1000 clinical trials have been or are being conducted to find ways to treat the disease, but it is unknown if any of the tested treatments will work. Because AD cannot be cured and is degenerative, the sufferer relies on others for assistance. The role of the main caregiver is often taken by the spouse or a close relative. Alzheimer's disease is known for placing a great burden on caregivers; the pressures can be wide-ranging, involving social, psychological, physical, and economic elements of the caregiver's life. In developed countries, AD is one of the most costly diseases to society. Research is the only hope to present and future patients and families suffering from this devastating disorder. This book compiles some of the most interesting articles on Alzheimer's disease published by PLoS journals lately: from epidemiology and prevention to management and treatment.

This volume is a companion to the highly successful book published in association with the Journal of Alzheimer’s Disease (JAD) on the centennial of Alzheimer’s discovery: “Alzheimer’s Disease: A Century of Scientific and Clinical Research”. Instead of looking back, this collection, “Alzheimer’s Disease: Advances for a New Century”, will look forward. Using scientometric analysis the most promising developments since the Alzheimer Centennial in 2006 have been substantiated. While prior trends and advances in genetics, amyloid-?, tau, neuropathology, and oxidative stress continue as active areas, emergent areas impacting the transition from normal cognition to Alzheimer’s disease such as diagnostic imaging, biomarkers, metabolism, and lifestyle (areas conceived only a few years ago) now dominate the debate. Invited contributors have summarized their landmark publications identified by our analysis and have put them into perspective, explaining the impetus behind the work, the contribution of the results to the field, and who played a role in the work.

"Providing a cross-section of current research, treatments and potential clinical developments, this volume of Advances in Pharmacology is an essential resource for biologists, pharmacologists and those engaged with Alzheimer's research."--P. [4] of cover.

Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.